{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:02:53Z","timestamp":1784592173286,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-05310-8","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T19:56:02Z","timestamp":1779738962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrative in silico transcriptomic and pharmacogenomic analysis of CD276 as a candidate prognostic biomarker and therapeutic target in bladder cancer"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2863-3243","authenticated-orcid":false,"given":"Faruk Recep","family":"\u00d6zalp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halil \u0130brahim","family":"Ellez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet Melih","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkut","family":"Demirciler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sava\u015f","family":"G\u00f6k\u00e7ek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oktay Halit","family":"Aktepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00fcseyin Salih","family":"Semiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz","family":"Karao\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"issue":"6","key":"5310_CR1","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41419-024-06837-w","volume":"15","author":"P Yu","year":"2024","unstructured":"Yu P, Zhu C, You X, Gu W, Wang X, Wang Y, et al. The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies. Cell Death Dis. 2024;15(6):433.","journal-title":"Cell Death Dis"},{"issue":"11","key":"5310_CR2","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.2217\/fon-2020-0967","volume":"17","author":"S Hu-Lieskovan","year":"2021","unstructured":"Hu-Lieskovan S, Malouf GG, Jacobs I, Chou J, Liu L, Johnson ML. Addressing resistance to immune checkpoint inhibitor therapy: an urgent unmet need. Future Oncol. 2021;17(11):1401\u201339.","journal-title":"Future Oncol"},{"issue":"1","key":"5310_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12943-023-01751-9","volume":"22","author":"AA Getu","year":"2023","unstructured":"Getu AA, Tigabu A, Zhou M, Lu J, Fodstad \u00d8, Tan M. New frontiers in immune checkpoint B7-H3 (CD276) research and drug development. Mol Cancer. 2023;22(1):43.","journal-title":"Mol Cancer"},{"key":"5310_CR4","doi-asserted-by":"publisher","first-page":"1445526","DOI":"10.3389\/fonc.2024.1445526","volume":"14","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, Xu J, Chen X, Ouyang J, Mao C, Zhang Z. CD276 as a promising diagnostic and prognostic biomarker for bladder cancer through bioinformatics and clinical research. Front Oncol. 2024;14:1445526.","journal-title":"Front Oncol"},{"issue":"12","key":"5310_CR5","doi-asserted-by":"publisher","first-page":"e0243379","DOI":"10.1371\/journal.pone.0243379","volume":"15","author":"T Azuma","year":"2020","unstructured":"Azuma T, Sato Y, Ohno T, Azuma M, Kume H. Serum soluble B7-H3 is a prognostic marker for patients with non-muscle-invasive bladder cancer. PLoS ONE. 2020;15(12):e0243379.","journal-title":"PLoS ONE"},{"issue":"10","key":"5310_CR6","doi-asserted-by":"publisher","first-page":"5167","DOI":"10.1002\/cam4.1775","volume":"7","author":"W Ma","year":"2018","unstructured":"Ma W, Ma J, Ma P, Lei T, Zhao M, Zhang M. Targeting immunotherapy for bladder cancer using anti-CD3\u00d7 B7-H3 bispecific antibody. Cancer Med. 2018;7(10):5167\u201377.","journal-title":"Cancer Med"},{"issue":"1","key":"5310_CR7","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1038\/s41467-024-46735-5","volume":"15","author":"M Cheng","year":"2024","unstructured":"Cheng M, Chen S, Li K, Wang G, Xiong G, Ling R, et al. CD276-dependent efferocytosis by tumor-associated macrophages promotes immune evasion in bladder cancer. Nat Commun. 2024;15(1):2818.","journal-title":"Nat Commun"},{"issue":"11","key":"5310_CR8","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/bco2.418","volume":"5","author":"ES Deol","year":"2024","unstructured":"Deol ES, Nabavizadeh R, Lavoie RR, Dumbrava MG, Horjeti E, Thapa P, et al. Role of B7-H3 in predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer. BJUI Compass. 2024;5(11):1052\u20138.","journal-title":"BJUI Compass"},{"issue":"W1","key":"5310_CR9","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z Tang","year":"2019","unstructured":"Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556\u201360.","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"5310_CR10","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.neo.2017.05.002","volume":"19","author":"DS Chandrashekar","year":"2017","unstructured":"Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649\u201358.","journal-title":"Neoplasia"},{"issue":"21","key":"5310_CR11","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1093\/bioinformatics\/bty411","volume":"34","author":"C-J Liu","year":"2018","unstructured":"Liu C-J, Hu F-F, Xia M-X, Han L, Zhang Q, Guo A-Y. GSCALite: a web server for gene set cancer analysis. Bioinformatics. 2018;34(21):3771\u20132.","journal-title":"Bioinformatics"},{"issue":"5","key":"5310_CR12","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.3390\/ijms22052622","volume":"22","author":"\u00c1 Bartha","year":"2021","unstructured":"Bartha \u00c1, Gy\u0151rffy B. Tnmplot.com: a web tool for the comparison of gene expression in normal, tumor and metastatic tissues. Int J Mol Sci. 2021;22(5):2622.","journal-title":"Int J Mol Sci"},{"issue":"D1","key":"5310_CR13","doi-asserted-by":"publisher","first-page":"D956","DOI":"10.1093\/nar\/gkx1090","volume":"46","author":"SV Vasaikar","year":"2018","unstructured":"Vasaikar SV, Straub P, Wang J, Zhang B. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2018;46(D1):D956-63.","journal-title":"Nucleic Acids Res"},{"issue":"43","key":"5310_CR14","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"W1","key":"5310_CR15","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"T Li","year":"2020","unstructured":"Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509\u201314.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"5310_CR16","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453\u20137.","journal-title":"Nat Methods"},{"issue":"5","key":"5310_CR17","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1158\/2767-9764.CRC-23-0546","volume":"4","author":"CD Miller","year":"2024","unstructured":"Miller CD, Lozada JR, Zorko NA, Elliott A, Makovec A, Radovich M, et al. Pan-cancer interrogation of B7-H3 (CD276) as an actionable therapeutic target across human malignancies. Cancer Res Commun. 2024;4(5):1369\u201379.","journal-title":"Cancer Res Commun"},{"issue":"1","key":"5310_CR18","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejso.2013.08.023","volume":"40","author":"E Xylinas","year":"2014","unstructured":"Xylinas E, Robinson BD, Kluth LA, Volkmer BG, Hautmann R, K\u00fcfer R, et al. Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. Eur J Surg Oncol. 2014;40(1):121\u20137.","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"5310_CR19","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.62347\/ILTR3848","volume":"17","author":"S Luan","year":"2025","unstructured":"Luan S, Zhao Y, Yu Y, Xu J, Xu J, Ren T, et al. The relevance of B7-H3 and tumor-associated macrophages in the tumor immune microenvironment of solid tumors: recent advances. Am J Transl Res. 2025;17(4):2835\u201349.","journal-title":"Am J Transl Res"},{"issue":"5","key":"5310_CR20","doi-asserted-by":"publisher","first-page":"816","DOI":"10.7150\/jca.17759","volume":"8","author":"Y Li","year":"2017","unstructured":"Li Y, Guo G, Song J, Cai Z, Yang J, Chen Z, et al. B7-H3 promotes the migration and invasion of human bladder cancer cells via the PI3K\/Akt\/STAT3 signaling pathway. J Cancer. 2017;8(5):816\u201324.","journal-title":"J Cancer"},{"key":"5310_CR21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12935-015-0195-z","volume":"15","author":"F-B Kang","year":"2015","unstructured":"Kang F-B, Wang L, Jia H-C, Li D, Li H-J, Zhang Y-G, et al. B7-H3 promotes aggression and invasion of hepatocellular carcinoma by targeting epithelial-to-mesenchymal transition via JAK2\/STAT3\/Slug signaling pathway. Cancer Cell Int. 2015;15:45.","journal-title":"Cancer Cell Int"},{"key":"5310_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2023.110737","volume":"109","author":"R Wu","year":"2023","unstructured":"Wu R, Zhang Y, Xu X, You Q, Yu C, Wang W, et al. Exosomal B7-H3 facilitates colorectal cancer angiogenesis and metastasis through AKT1\/mTOR\/VEGFA pathway. Cell Signal. 2023;109:110737.","journal-title":"Cell Signal"},{"issue":"8","key":"5310_CR23","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1158\/0008-5472.CAN-15-1538","volume":"76","author":"S Lim","year":"2016","unstructured":"Lim S, Liu H, Madeira da Silva L, Arora R, Liu Z, Phillips JB, et al. Immunoregulatory protein B7-H3 reprograms glucose metabolism in cancer cells by ROS-mediated stabilization of HIF1\u03b1. Cancer Res. 2016;76(8):2231\u201342.","journal-title":"Cancer Res"},{"issue":"1","key":"5310_CR24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1158\/2326-6066.CIR-21-0407","volume":"10","author":"T Miyamoto","year":"2022","unstructured":"Miyamoto T, Murakami R, Hamanishi J, Tanigaki K, Hosoe Y, Mise N, et al. B7-H3 suppresses antitumor immunity via the CCL2-CCR2-M2 macrophage axis and contributes to ovarian cancer progression. Cancer Immunol Res. 2022;10(1):56\u201369.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"5310_CR25","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3892\/or.2014.3587","volume":"33","author":"F-B Kang","year":"2015","unstructured":"Kang F-B, Wang L, Li D, Zhang Y-G, Sun D-X. Hepatocellular carcinomas promote tumor-associated macrophage M2-polarization via increased B7-H3 expression. Oncol Rep. 2015;33(1):274\u201382.","journal-title":"Oncol Rep"},{"issue":"9","key":"5310_CR26","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.7150\/jca.90819","volume":"15","author":"Y Wu","year":"2024","unstructured":"Wu Y, Han W, Tang X, Liu J, Guo Z, Li Z, et al. B7-H3 suppresses CD8\u2009+\u2009T cell immunologic function through reprogramming glycolytic metabolism. J Cancer. 2024;15(9):2505\u201317.","journal-title":"J Cancer"},{"issue":"13","key":"5310_CR27","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.3390\/cancers15133530","volume":"15","author":"S Alhamad","year":"2023","unstructured":"Alhamad S, Elmasry Y, Uwagboe I, Chekmeneva E, Sands C, Cooper BW, et al. B7-H3 associates with IMPDH2 and regulates cancer cell survival. Cancers (Basel). 2023;15(13):3530.","journal-title":"Cancers (Basel)"},{"issue":"6suppl","key":"5310_CR28","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1200\/JCO.2023.41.6_suppl.548","volume":"41","author":"A Mahmoud","year":"2023","unstructured":"Mahmoud A, Frank I, Ahmed ME, Orme J, Lavoie R, Thapa P, et al. Evaluation of PD-L1 and B7-H3 expression as a predictor of response to adjuvant chemotherapy in bladder cancer. JCO. 2023;41(6suppl):548\u2013548.","journal-title":"JCO"},{"key":"5310_CR29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-02142","author":"CM Rudin","year":"2025","unstructured":"Rudin CM, Johnson ML, Paz-Ares L, Nishio M, Hann CL, Girard N, et al. Ifinatamab deruxtecan in patients with extensive-stage small cell lung cancer: primary analysis of the phase II IDeate-Lung01 trial. J Clin Oncol. 2025. https:\/\/doi.org\/10.1200\/JCO-25-02142.","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"5310_CR30","doi-asserted-by":"publisher","first-page":"TPS3157","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS3157","volume":"43","author":"T Kogawa","year":"2025","unstructured":"Kogawa T, Mitani S, Berz D, Reis D, Li C, Ishida TC, et al. IDeate-PanTumor02: a phase 1b\/2 study to evaluate the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients (pts) with recurrent or metastatic solid tumors. JCO. 2025;43(16_suppl):TPS3157.","journal-title":"JCO"},{"issue":"6","key":"5310_CR31","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1080\/13543784.2025.2512566","volume":"34","author":"M Wespiser","year":"2025","unstructured":"Wespiser M, Gille R, P\u00e9rol M. Clinical progress of B7-H3 targeted antibody drug conjugate ifinatamab deruxtecan for small-cell lung cancer. Expert Opin Investig Drugs. 2025;34(6):463\u201371.","journal-title":"Expert Opin Investig Drugs"},{"key":"5310_CR32","doi-asserted-by":"publisher","first-page":"S657","DOI":"10.1016\/j.annonc.2021.08.1133","volume":"32","author":"E Shenderov","year":"2021","unstructured":"Shenderov E, Mallesara GHG, Wysocki PJ, Xu W, Ramlau R, Weickhardt AJ, et al. 620P MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors: Preliminary results of phase I cohort expansion. Ann Oncol. 2021;32:S657-9.","journal-title":"Ann Oncol"},{"issue":"1","key":"5310_CR33","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13045-025-01729-8","volume":"18","author":"B Kristmann","year":"2025","unstructured":"Kristmann B, Werchau N, Suresh L, Pezzuto EL, Scheuermann S, Krost S, et al. Targeting CD276 with Adapter-CAR T-cells provides a novel therapeutic strategy in small cell lung cancer and prevents CD276-dependent fratricide. J Hematol Oncol. 2025;18(1):76.","journal-title":"J Hematol Oncol"},{"key":"5310_CR34","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3389\/fonc.2018.00264","volume":"8","author":"P Dong","year":"2018","unstructured":"Dong P, Xiong Y, Yue J, Hanley SJB, Watari H. B7H3 as a promoter of metastasis and promising therapeutic target. Front Oncol. 2018;8:264.","journal-title":"Front Oncol"},{"issue":"16","key":"5310_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202415577","volume":"12","author":"S Zhou","year":"2025","unstructured":"Zhou S, Hong M, Zhao D, Li W, Yuan X, Wang Y, et al. Reprogramming the tumor immune microenvironment with ICAM-1-targeted antibody\u2012drug conjugates and B7-H3-CD3 bispecific antibodies. Adv Sci. 2025;12(16):e2415577.","journal-title":"Adv Sci"},{"issue":"1","key":"5310_CR36","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12935-025-04133-x","volume":"26","author":"H Dai","year":"2026","unstructured":"Dai H, Zhang X, Yin L, Chen H, Liu K, Li J, et al. Integrating machine learning and multi-omics analysis to explore Treg-associated programmed cell death features in clear cell renal cell carcinoma. Cancer Cell Int. 2026;26(1):15.","journal-title":"Cancer Cell Int"},{"issue":"4","key":"5310_CR37","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.ccell.2025.03.012","volume":"43","author":"J Luo","year":"2025","unstructured":"Luo J, Solit DB. Leveraging real-world data to advance biomarker discovery and precision oncology. Cancer Cell. 2025;43(4):606\u201310.","journal-title":"Cancer Cell"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05310-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05310-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05310-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:07:49Z","timestamp":1784588869000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05310-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5310"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05310-8","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"9 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This study is based exclusively on publicly available datasets (TCGA, GTEx, and other open-access resources) and did not involve human participants or animal experiments requiring ethical approval.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1050"}}